Breaking Finance News

Cryolife Inc (NYSE:CRY) has been downgraded to Hold in a report by Zacks Investment Research today.

Having a price of $16.88, Cryolife Inc (NYSE:CRY) traded -4.31% lower on the day. The last stock close price is up 24.28% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. Cryolife Inc has recorded a 50-day average of $17.12 and a two hundred day average of $13.58. Trading volume was up over the average, with 521,449 shares of CRY changing hands over the typical 299,611

Zacks Investment Research has downgraded Cryolife Inc (NYSE:CRY) to Hold in a statement released on 10/11/2016.

Performance Chart

Cryolife Inc (NYSE:CRY)

With a total market value of $0, Cryolife Inc has 52 week low of $8.94 and a 52 week high of $18.64 with a PE ratio of 54.10 .

In addition to Zacks Investment Research reporting its stock price target, a total of 4 brokerages have issued a ratings update on the company. The average stock price target is $13.75 with 3 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Cryolife Inc (NYSE:CRY)

CryoLife, Inc. (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol). The Preservation Services segment preserves cardiac and vascular tissues. The Company's surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), and PerClot, an absorbable powdered hemostat, which the Company distributes internationally for Starch Medical, Inc. (SMI). Its CardioGenesis cardiac laser therapy product line includes a laser console system and single-use, fiber-optic handpieces.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.